Genetic Prognostic Factors in Multiple Sclerosis: Toward Precision Neurology
Multiple sclerosis (MS) is a chronic autoimmune and neurodegenerative disorder characterized by substantial clinical and radiological heterogeneity. Although modern neurology has made major progress in identifying genetic factors that increase susceptibility to MS, predicting how the disease will evolve in an individual patient remains difficult. Prognosis depends on multiple domains, including age at onset, relapse activity, disability progression, cognitive impairment, MRI lesion burden, brain and spinal cord atrophy, and cerebrospinal fluid biomarkers. The reviewed article emphasizes that genetic influences on MS prognosis are generally modest, heterogeneous, and not yet suitable for routine clinical stratification.
Genetic Architecture: From Risk to Disease Course
MS susceptibility is highly polygenic, with more than 230 common genetic variants contributing to disease risk and approximately 48% of SNP-based heritability explained by common variants. The HLA region, especially HLA-DRB1*15:01, remains the strongest genetic risk factor, while rare variants, epigenetic mechanisms, gene–gene interactions, and gene–environment interactions likely account for additional unexplained heritability. However, the genetic determinants of prognosis appear only partially overlapping with susceptibility loci, suggesting that the biology of developing MS and the biology of accumulating disability may not be identical.
Age at Onset and Early Clinical Expression
Age at onset is an important prognostic dimension because pediatric-onset, adult-onset, and late-onset MS often differ in clinical trajectory. The review reports that HLA-DRB1*15:01 has been associated with a modest but reproducible reduction in age at onset, whereas many non-HLA candidate-gene findings remain inconsistent or unreplicated. Polygenic risk approaches suggest that a higher MS genetic burden may accelerate onset in some disease forms, although dedicated genome-wide studies of age at onset have not yet produced robust and consistently replicated loci.
Relapse Activity, Disability, and Disease Severity
Relapse rate and disability progression are central clinical outcomes in MS, but they are difficult to study genetically because they are influenced by follow-up duration, treatment exposure, phenotype definitions, and measurement limitations. Some genome-wide evidence implicates LRP2 in annualized relapse rate, while the largest GWAS of age-related Multiple Sclerosis Severity Score identified a DYSF–ZNF638 region associated with disease severity. Nevertheless, most disability-related associations from candidate-gene studies remain preliminary, and traditional measures such as EDSS are limited by non-linearity and strong dependence on ambulation.
Cognition and Neuroimaging as Intermediate Phenotypes
Cognitive impairment affects a substantial proportion of individuals with MS and may arise independently of motor disability. Genetic studies of cognition have focused mainly on candidate genes such as APOE and BDNF, but findings remain inconsistent, and large GWASs specifically targeting cognitive impairment are still lacking. By contrast, MRI-based phenotypes, including thalamic atrophy, brain volume loss, lesion burden, and spinal cord atrophy, may provide more objective intermediate measures of disease biology. The review highlights that polygenic susceptibility has been associated with longitudinal thalamic atrophy, making imaging outcomes promising tools for future prognostic genetics.
Fluid Biomarkers and Intrathecal Immune Activity
Cerebrospinal fluid biomarkers provide some of the strongest evidence for genetic influence on MS prognosis-related biology. Oligoclonal bands and elevated IgG index reflect intrathecal humoral immune activity, and large multi-cohort GWASs have identified associations involving HLA haplotypes, the immunoglobulin heavy chain locus, and the SAMD5 gene. These findings are particularly important because CSF biomarkers may be closer to pathogenic mechanisms than broad clinical outcomes. The review also notes emerging links between genetic variants and neuroaxonal injury markers such as serum neurofilament light chain.
Clinical Translation and Future Directions
At present, genetic markers cannot yet be used routinely to predict MS prognosis in clinical practice. The main barriers are modest effect sizes, limited replication, small sample sizes, heterogeneity in outcome definitions, European ancestry bias, and confounding by disease-modifying therapies. Future progress will require large, longitudinal, multi-ancestry cohorts integrating genomic data with MRI, OCT, CSF, blood biomarkers, and standardized clinical phenotypes. The most realistic path toward precision neurology is not a single prognostic variant, but a multidimensional prognostic score combining genetic, epigenetic, clinical, imaging, and fluid biomarker information to support individualized treatment decisions.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Ciampana, V., Virgilio, E., Paciolla, L., Asaro, S., Franceschini, A., Thavamani, M., ... & Vecchio, D. (2026). Genetic Prognostic Factors in Multiple Sclerosis: Key Discoveries and Unmet Needs. International Journal of Molecular Sciences, 27(8), 3583.
